Seattle Genetics to acquire Cascadian Therapeutics, adding late-stage breast cancer program to its oncology pipeline. Seattle Genetics, Inc. and Cascadian Therapeutics, Inc. have signed a definitive merger agreement under which Seattle Genetics has agreed to acquire Cascadian Therapeutics. Under the terms of the agreement, Seattle Genetics will pay $10 per share in cash, or approximately $614 million.…
Hodgkin Lymphoma Treatment Receives FDA Breakthrough Therapy Designation
Fatalities Lead to Clinical Hold on Seattle Genetics’ Cancer Drug
Seattle Genetics announces clinical hold on several Phase 1 trials of vadastuximab talirine (SGN-CD33A). Seattle Genetics, Inc., a global biotechnology company, last week announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab…